Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
Status:
Completed
Trial end date:
2017-10-24
Target enrollment:
Participant gender:
Summary
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal
thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12
weeks in patients with mild vision impairment due to center-involved DME